Home > Journals > Panminerva Medica > Past Issues > Articles online first > Panminerva Medica 2020 Sep 21

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

Panminerva Medica 2020 Sep 21

DOI: 10.23736/S0031-0808.20.04125-7

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Old and new generation immunomodulatory drugs in multiple myeloma

Daniele DERUDAS 1 , Francesca CAPRARO 1, Giovanni MARTINELLI 2, Claudio CERCHIONE 2

1 S.C. di Ematologia e C.T.M.O., Ospedale Oncologico di Riferimento Regionale “A. Businco”, Cagliari, Italy; 2 Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Merola, Forlì Cesena, Italy


PDF


INTRODUCTION: Over the last two decades, the outcomes of patients with multiple myeloma (MM), a malignant plasma cells dyscrasia, have dramatically improved. The development and the introduction of the immunomodulatory drugs (IMiDs) which include thalidomide, lenalidomide, and pomalidomide, has contributed significantly to these improvements.
EVIDENCE ACQUISITION: The IMiDs have been shown a multitude of mechanisms of action, including anti-angiogenic, cytotoxic, and immunomodulatory. The more recent discoveries that the IMiDs bind to cereblon and thus regulate the ubiquitination of key transcription factors including IKZF1 and IKZF3, have provided new insight about their activities.
EVIDENCE SYNTHESIS: The IMIDs are widely used in the treatment of the different setting of MM patients and particularly lenalidomide represents the backbone in the therapy of newly diagnosed transplant eligible and transplant ineligible patients, in the maintenance setting post-transplant and in the relapsed/refractory setting, while pomalidomide is currently utilized in the relapsed/refractory setting.
CONCLUSIONS: Here the mechanisms of action, the clinical efficacy and the management of side effects are reviewed as well as the new classes of cereblon E3 ligase modulator (CELMoD) and their promising clinical data are described.


KEY WORDS: Multiple myeloma; Immunotherapy; Immunologic factors; Immunotherapy

top of page